Therapy for children with invasive pneumococcal infections

N. A. Halsey, P. J. Chesney, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, M. I. Marks, D. L. Murray, Jr Overall, L. K. Pickering, R. J. Whitley, R. Yogev, G. Peter, C. B. Hall, R. Breiman, S. C. Hadler, M. C. Hardegree, R. F. Jacobs, N. E. MacDonald, W. A. Orenstein & 5 others N. R. Rabinovich, B. Schwartz, Jr McCracken, S. L. Kaplan, J. H. Jorgensen

Research output: Contribution to journalReview article

158 Citations (Scopus)

Abstract

This statement provides guidelines for therapy of children with serious infections possibly caused by Streptococcus pneumoniae. Resistance of invasive pneumococcal strains to penicillin, cefotaxime, and ceftriaxone has increased over the past few years. Reports of failures of cefotaxime or ceftriaxone in the treatment of children with meningitis caused by resistant S pneumoniae necessitates a revision of Academy recommendations. For nonmeningeal infections, modifications of the initial therapy need to be considered only for patients who are critically ill and those who have a severe underlying or potentially immunocompromising condition or patients from whom a highly resistant strain is isolated. Because vancomycin is the only antibiotic to which all S pneumoniae strains are susceptible, its use should be restricted to minimize the emergence of vancomycin-resistant organisms. Patients with probable aseptic (viral) meningitis should not be treated with vancomycin. These recommendations are subject to change as new information becomes available.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalPediatrics
Volume99
Issue number2
DOIs
StatePublished - Feb 1 1997

Fingerprint

Pneumococcal Infections
Vancomycin
Cefotaxime
Ceftriaxone
Pneumonia
Viral Meningitis
Aseptic Meningitis
Streptococcus pneumoniae
Infection
Meningitis
Critical Illness
Penicillins
Therapeutics
Guidelines
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Chesney, P. J., Gerber, M. A., Gromisch, D. S., Kohl, S., Marcy, S. M., ... Jorgensen, J. H. (1997). Therapy for children with invasive pneumococcal infections. Pediatrics, 99(2), 289-299. https://doi.org/10.1542/peds.99.2.289

Therapy for children with invasive pneumococcal infections. / Halsey, N. A.; Chesney, P. J.; Gerber, M. A.; Gromisch, D. S.; Kohl, S.; Marcy, S. M.; Marks, M. I.; Murray, D. L.; Overall, Jr; Pickering, L. K.; Whitley, R. J.; Yogev, R.; Peter, G.; Hall, C. B.; Breiman, R.; Hadler, S. C.; Hardegree, M. C.; Jacobs, R. F.; MacDonald, N. E.; Orenstein, W. A.; Rabinovich, N. R.; Schwartz, B.; McCracken, Jr; Kaplan, S. L.; Jorgensen, J. H.

In: Pediatrics, Vol. 99, No. 2, 01.02.1997, p. 289-299.

Research output: Contribution to journalReview article

Halsey, NA, Chesney, PJ, Gerber, MA, Gromisch, DS, Kohl, S, Marcy, SM, Marks, MI, Murray, DL, Overall, J, Pickering, LK, Whitley, RJ, Yogev, R, Peter, G, Hall, CB, Breiman, R, Hadler, SC, Hardegree, MC, Jacobs, RF, MacDonald, NE, Orenstein, WA, Rabinovich, NR, Schwartz, B, McCracken, J, Kaplan, SL & Jorgensen, JH 1997, 'Therapy for children with invasive pneumococcal infections', Pediatrics, vol. 99, no. 2, pp. 289-299. https://doi.org/10.1542/peds.99.2.289
Halsey NA, Chesney PJ, Gerber MA, Gromisch DS, Kohl S, Marcy SM et al. Therapy for children with invasive pneumococcal infections. Pediatrics. 1997 Feb 1;99(2):289-299. https://doi.org/10.1542/peds.99.2.289
Halsey, N. A. ; Chesney, P. J. ; Gerber, M. A. ; Gromisch, D. S. ; Kohl, S. ; Marcy, S. M. ; Marks, M. I. ; Murray, D. L. ; Overall, Jr ; Pickering, L. K. ; Whitley, R. J. ; Yogev, R. ; Peter, G. ; Hall, C. B. ; Breiman, R. ; Hadler, S. C. ; Hardegree, M. C. ; Jacobs, R. F. ; MacDonald, N. E. ; Orenstein, W. A. ; Rabinovich, N. R. ; Schwartz, B. ; McCracken, Jr ; Kaplan, S. L. ; Jorgensen, J. H. / Therapy for children with invasive pneumococcal infections. In: Pediatrics. 1997 ; Vol. 99, No. 2. pp. 289-299.
@article{a6c7bf29f07f4782aa114d9c4d1591ab,
title = "Therapy for children with invasive pneumococcal infections",
abstract = "This statement provides guidelines for therapy of children with serious infections possibly caused by Streptococcus pneumoniae. Resistance of invasive pneumococcal strains to penicillin, cefotaxime, and ceftriaxone has increased over the past few years. Reports of failures of cefotaxime or ceftriaxone in the treatment of children with meningitis caused by resistant S pneumoniae necessitates a revision of Academy recommendations. For nonmeningeal infections, modifications of the initial therapy need to be considered only for patients who are critically ill and those who have a severe underlying or potentially immunocompromising condition or patients from whom a highly resistant strain is isolated. Because vancomycin is the only antibiotic to which all S pneumoniae strains are susceptible, its use should be restricted to minimize the emergence of vancomycin-resistant organisms. Patients with probable aseptic (viral) meningitis should not be treated with vancomycin. These recommendations are subject to change as new information becomes available.",
author = "Halsey, {N. A.} and Chesney, {P. J.} and Gerber, {M. A.} and Gromisch, {D. S.} and S. Kohl and Marcy, {S. M.} and Marks, {M. I.} and Murray, {D. L.} and Jr Overall and Pickering, {L. K.} and Whitley, {R. J.} and R. Yogev and G. Peter and Hall, {C. B.} and R. Breiman and Hadler, {S. C.} and Hardegree, {M. C.} and Jacobs, {R. F.} and MacDonald, {N. E.} and Orenstein, {W. A.} and Rabinovich, {N. R.} and B. Schwartz and Jr McCracken and Kaplan, {S. L.} and Jorgensen, {J. H.}",
year = "1997",
month = "2",
day = "1",
doi = "10.1542/peds.99.2.289",
language = "English (US)",
volume = "99",
pages = "289--299",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "2",

}

TY - JOUR

T1 - Therapy for children with invasive pneumococcal infections

AU - Halsey, N. A.

AU - Chesney, P. J.

AU - Gerber, M. A.

AU - Gromisch, D. S.

AU - Kohl, S.

AU - Marcy, S. M.

AU - Marks, M. I.

AU - Murray, D. L.

AU - Overall, Jr

AU - Pickering, L. K.

AU - Whitley, R. J.

AU - Yogev, R.

AU - Peter, G.

AU - Hall, C. B.

AU - Breiman, R.

AU - Hadler, S. C.

AU - Hardegree, M. C.

AU - Jacobs, R. F.

AU - MacDonald, N. E.

AU - Orenstein, W. A.

AU - Rabinovich, N. R.

AU - Schwartz, B.

AU - McCracken, Jr

AU - Kaplan, S. L.

AU - Jorgensen, J. H.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - This statement provides guidelines for therapy of children with serious infections possibly caused by Streptococcus pneumoniae. Resistance of invasive pneumococcal strains to penicillin, cefotaxime, and ceftriaxone has increased over the past few years. Reports of failures of cefotaxime or ceftriaxone in the treatment of children with meningitis caused by resistant S pneumoniae necessitates a revision of Academy recommendations. For nonmeningeal infections, modifications of the initial therapy need to be considered only for patients who are critically ill and those who have a severe underlying or potentially immunocompromising condition or patients from whom a highly resistant strain is isolated. Because vancomycin is the only antibiotic to which all S pneumoniae strains are susceptible, its use should be restricted to minimize the emergence of vancomycin-resistant organisms. Patients with probable aseptic (viral) meningitis should not be treated with vancomycin. These recommendations are subject to change as new information becomes available.

AB - This statement provides guidelines for therapy of children with serious infections possibly caused by Streptococcus pneumoniae. Resistance of invasive pneumococcal strains to penicillin, cefotaxime, and ceftriaxone has increased over the past few years. Reports of failures of cefotaxime or ceftriaxone in the treatment of children with meningitis caused by resistant S pneumoniae necessitates a revision of Academy recommendations. For nonmeningeal infections, modifications of the initial therapy need to be considered only for patients who are critically ill and those who have a severe underlying or potentially immunocompromising condition or patients from whom a highly resistant strain is isolated. Because vancomycin is the only antibiotic to which all S pneumoniae strains are susceptible, its use should be restricted to minimize the emergence of vancomycin-resistant organisms. Patients with probable aseptic (viral) meningitis should not be treated with vancomycin. These recommendations are subject to change as new information becomes available.

UR - http://www.scopus.com/inward/record.url?scp=0030993807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030993807&partnerID=8YFLogxK

U2 - 10.1542/peds.99.2.289

DO - 10.1542/peds.99.2.289

M3 - Review article

VL - 99

SP - 289

EP - 299

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 2

ER -